Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 20, 2014, 118 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $277.00 to $8,954,563.40.

Highlighted Stocks Traded by Insiders:

Conmed (CNMD) - FREE Research Report

Darling Joseph G, who is EVP, Commercial Operations at Conmed, sold 4,270 shares at $42.00 on Nov. 20, 2014. Following this transaction, the EVP, Commercial Operations owned 12,015 shares meaning that the stake was reduced by 26.22% with the 4,270-share transaction.

The shares most recently traded at $41.97, down $0.03, or 0.07% since the insider transaction. Historical insider transactions for Conmed go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 7,423
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 7,423
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 9,023

The average volume for Conmed has been 169,100 shares per day over the past 30 days. Conmed has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are down 1.84% year-to-date as of the close of trading on Thursday.

CONMED Corporation provides surgical devices and equipment for minimally invasive procedures and monitoring. The stock currently has a dividend yield of 1.92%. The company has a P/E ratio of 37.2. Currently, there is 1 analyst who rates Conmed a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNMD - FREE

TheStreet Quant Ratings

rates Conmed as a

buy

. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Conmed Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Furmanite (FRM) - FREE Research Report

Cox Charles R, who is Chief Executive Officer at Furmanite, bought 5,058 shares at $6.34 on Nov. 20, 2014. Following this transaction, the Chief Executive Officer owned 469,631 shares meaning that the stake was boosted by 1.09% with the 5,058-share transaction.

The shares most recently traded at $6.64, up $0.30, or 4.52% since the insider transaction. Historical insider transactions for Furmanite go as follows:

  • 4-Week # shares bought: 24,855
  • 12-Week # shares bought: 24,855
  • 24-Week # shares bought: 24,855

The average volume for Furmanite has been 255,700 shares per day over the past 30 days. Furmanite has a market cap of $237.0 million and is part of the services sector and diversified services industry. Shares are down 38.79% year-to-date as of the close of trading on Thursday.

Furmanite Corporation, together with its subsidiaries, provides specialized technical services. It operates in two segments, Technical Services and Engineering & Project Solutions. The company has a P/E ratio of 26.2. Currently, there are no analysts who rate Furmanite a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FRM - FREE

TheStreet Quant Ratings

rates Furmanite as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full

Furmanite Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

LTC Properties (LTC) - FREE Research Report

Triche Timothy, who is Director at LTC Properties, sold 5,000 shares at $40.90 on Nov. 20, 2014. Following this transaction, the Director owned 29,302 shares meaning that the stake was reduced by 14.58% with the 5,000-share transaction.

The shares most recently traded at $40.98, up $0.08, or 0.19% since the insider transaction. Historical insider transactions for LTC Properties go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 1,000

The average volume for LTC Properties has been 152,800 shares per day over the past 30 days. LTC Properties has a market cap of $1.4 billion and is part of the financial sector and real estate industry. Shares are up 15.65% year-to-date as of the close of trading on Thursday.

LTC Properties, Inc. operates as a health care real estate investment trust (REIT) in the United States. The stock currently has a dividend yield of 5.02%. The company has a P/E ratio of 22.3. Currently, there is 1 analyst who rates LTC Properties a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LTC - FREE

TheStreet Quant Ratings

rates LTC Properties as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

LTC Properties Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null